Obstructive Sleep Apnea — Diagnosis, CPAP, and Cardiovascular Consequences

Obstructive Sleep Apnea (OSA) is characterized by repetitive episodes of complete (apnea) or partial (hypopnea) upper airway obstruction during sleep, leading to intermittent hypoxemia, sleep fragmentation, and excessive daytime sleepiness.

[KEY_CONCEPT] OSA affects approximately 4% of middle-aged men and 2% of middle-aged women, with prevalence increasing dramatically with age and obesity. Risk factors include male sex, obesity (BMI >30), advanced age, family history, and anatomical factors such as large neck circumference (>17 inches in men, >16 inches in women).

Pathophysiology

Upper airway collapse occurs due to:

• Anatomical factors: Narrow pharyngeal space, enlarged soft tissues (tongue, soft palate, uvula)
• Functional factors: Reduced pharyngeal dilator muscle tone during sleep
• Neural factors: Impaired upper airway reflexes

[CLINICAL_PEARL] The pharynx lacks rigid structural support unlike the trachea and bronchi, making it susceptible to collapse during the negative inspiratory pressures generated during sleep.

Consequences of repetitive obstruction:

1. Intermittent hypoxemia → sympathetic activation
2. Arousal responses → sleep fragmentation
3. Intrathoracic pressure swings → cardiac stress
4. Systemic inflammation → endothelial dysfunction

This cascade leads to cardiovascular consequences including hypertension, coronary artery disease, stroke, and heart failure. The hypoxia-reoxygenation cycles generate reactive oxygen species, contributing to atherosclerosis and metabolic dysfunction.

Primary Symptoms

Nighttime symptoms:

• Loud snoring (reported by bed partner)
• Witnessed apneas or gasping episodes
• Frequent awakenings or restless sleep
• Nocturia (≥2 episodes per night)

Daytime symptoms:

• Excessive daytime sleepiness (most common presenting complaint)
• Morning headaches
• Difficulty concentrating or memory problems
• Irritability or mood changes

[HIGH_YIELD] The Epworth Sleepiness Scale (ESS) is a validated tool for assessing daytime sleepiness. Scores >10 suggest excessive daytime sleepiness warranting further evaluation.

Physical Examination Findings

[CLINICAL_PEARL] Mallampati classification assesses oral cavity crowding: Class III-IV (only soft palate visible) correlates with higher OSA risk.

STOP-BANG Questionnaire

A validated screening tool with 8 yes/no questions:

• Snoring loudly
• Tiredness/sleepiness during day
• Observed apneas
• Pressure (hypertension)
• BMI >35
• Age >50
• Neck circumference >16"/17"
• Gender (male)

[HIGH_YIELD] STOP-BANG ≥3 has high sensitivity (83-93%) for moderate-severe OSA, making it an excellent screening tool in primary care and preoperative settings.

Diagnostic Criteria for OSA

Required: Documentation of sleep-related breathing events PLUS either:

1. ≥5 predominantly obstructive respiratory events/hour with symptoms OR
2. ≥15 predominantly obstructive respiratory events/hour regardless of symptoms

Sleep Study Types

Polysomnography (PSG) - Gold Standard

In-laboratory overnight study measuring:

• EEG (sleep stages)
• EOG (eye movements)
• EMG (muscle tone)
• Respiratory effort (chest/abdominal bands)
• Airflow (nasal pressure transducer)
• Oxygen saturation
• Body position

Home Sleep Apnea Testing (HSAT)

Portable monitors measuring 3-4 channels:

• Airflow
• Respiratory effort
• Oxygen saturation
• ± Body position

[KEY_CONCEPT] HSAT is appropriate for patients with high pretest probability and no comorbid sleep disorders. PSG remains gold standard for complex cases.

Apnea-Hypopnea Index (AHI) Classification

OSA Severity Classification:

┌─────────────────────────────────────────┐ │ Normal: AHI < 5 events/hour │ │ Mild: AHI 5-14 events/hour │ │ Moderate: AHI 15-29 events/hour │ │ Severe: AHI ≥ 30 events/hour │ └─────────────────────────────────────────┘

[CLINICAL_PEARL] Oxygen Desaturation Index (ODI) ≥4% drops correlates well with AHI and may be more predictive of cardiovascular outcomes.

Differential Diagnosis

Treatment Algorithm

OSA Treatment Approach:

Mild OSA (AHI 5-14) ├── Asymptomatic → Lifestyle modifications └── Symptomatic → CPAP or Oral Appliances

Moderate OSA (AHI 15-29) └── CPAP therapy (first-line) ├── Alternative: Oral appliances └── Alternative: Positional therapy

Severe OSA (AHI ≥30) └── CPAP therapy (mandatory) ├── If CPAP intolerant → BiPAP or ASV └── Surgical options if non-PAP failures

Continuous Positive Airway Pressure (CPAP)

[KEY_CONCEPT] CPAP is first-line therapy for moderate-severe OSA, providing pneumatic splinting of the upper airway.

CPAP Components:

• Pressure generator (4-20 cmH₂O)
• Heated humidifier (reduces dryness)
• Interface (nasal mask, full-face mask, nasal pillows)
• Heated tubing (prevents condensation)

Auto-adjusting PAP (APAP) varies pressure automatically based on flow limitation, providing optimal comfort and efficacy.

Lifestyle Modifications

Weight Management:

• 10% weight loss can reduce AHI by 25-30%
• Bariatric surgery for BMI >35 with comorbidities

Sleep Hygiene:

• Positional therapy (avoid supine sleep)
• Alcohol avoidance (reduces upper airway muscle tone)
• Smoking cessation (reduces airway inflammation)

[CLINICAL_PEARL] Positional OSA (supine AHI ≥2× non-supine AHI) affects 50-60% of patients with mild-moderate disease.

Alternative Therapies

Oral Appliances:

• Mandibular advancement devices (MAD)
• Effective for mild-moderate OSA
• Alternative when CPAP intolerant

Surgical Options (when conservative measures fail):

• Uvulopalatopharyngoplasty (UPPP)
• Maxillomandibular advancement
• Hypoglossal nerve stimulation (Inspire therapy)

CPAP Adherence Optimization

[HIGH_YIELD] CPAP adherence defined as ≥4 hours/night for ≥70% of nights. Poor adherence associated with persistent cardiovascular risk.

Strategies to improve adherence:

• Proper mask fitting
• Gradual pressure acclimatization
• Heated humidification
• Patient education and ongoing support
• Treatment of nasal congestion

Major Cardiovascular Consequences

[HIGH_YIELD] OSA significantly increases cardiovascular morbidity and mortality through multiple mechanisms:

Hypertension

• 50% of OSA patients have hypertension
• Resistant hypertension strongly associated with OSA
• CPAP therapy reduces blood pressure by 2-10 mmHg
• Mechanism: Sympathetic activation and endothelial dysfunction

Coronary Artery Disease

• 2-3x increased risk of myocardial infarction
• Nocturnal cardiac events more common in OSA
• CPAP reduces major adverse cardiac events (MACE)

[CLINICAL_PEARL] Morning myocardial infarctions are more frequent in OSA patients due to surge in sympathetic activity and blood pressure upon awakening.

Heart Failure

• OSA prevalence >50% in heart failure patients
• Central sleep apnea often coexists with systolic dysfunction
• CPAP improves left ventricular ejection fraction

Arrhythmias

Metabolic Consequences

Insulin Resistance:

• Sleep fragmentation impairs glucose metabolism
• Intermittent hypoxia promotes insulin resistance
• Type 2 diabetes risk increased 1.5-2x

Dyslipidemia:

• Elevated triglycerides and reduced HDL
• Increased small dense LDL particles
• CPAP therapy modestly improves lipid profile

Neurocognitive Complications

Stroke Risk:

• 2-3x increased stroke risk
• Both ischemic and hemorrhagic subtypes
• CPAP therapy may reduce recurrent stroke risk

Cognitive Impairment:

• Executive dysfunction and memory deficits
• Increased dementia risk in elderly
• CPAP improves attention and psychomotor function

[KEY_CONCEPT] Untreated severe OSA carries mortality risk equivalent to moderate-heavy smoking (2-3x increased all-cause mortality).

Perioperative Complications

Increased Risk:

• Difficult intubation (30% vs 5% in controls)
• Postoperative respiratory depression
• Cardiovascular events
• Delayed recovery and prolonged hospital stay

CPAP therapy significantly reduces perioperative complications and should be continued postoperatively.

Treatment Outcomes with CPAP

Symptom Improvement:

• Excessive daytime sleepiness resolves in 80-90% of adherent patients
• Cognitive function improves within 2-4 weeks
• Quality of life significantly enhanced
• Partner sleep quality also improves

Cardiovascular Benefits:

• Blood pressure reduction: 2-10 mmHg decrease
• Reduced MACE: 20-30% risk reduction in adherent patients
• Arrhythmia reduction: Particularly atrial fibrillation
• Heart failure: Improved ejection fraction and symptoms

[HIGH_YIELD] CPAP adherence ≥4 hours/night is the minimum threshold for cardiovascular benefit, but optimal benefit requires ≥6-7 hours/night.

Follow-up Protocol

Initial Follow-up (1-3 months)

• CPAP adherence review (download data)
• Symptom assessment (ESS, subjective improvement)
• Mask fit evaluation
• Pressure optimization
• Side effect management

Long-term Follow-up (6-12 months)

• Annual CPAP data download
• Cardiovascular risk factor monitoring
• Weight management counseling
• Equipment replacement (masks every 3 months, tubing every 6 months)

Prognosis Factors

Favorable Prognosis:

• Good CPAP adherence (>6 hours/night)
• Younger age at diagnosis
• Absence of significant comorbidities
• Successful weight management

Poor Prognosis:

• Severe untreated OSA (AHI >30)
• CPAP non-adherence
• Multiple cardiovascular comorbidities
• Persistent obesity

[CLINICAL_PEARL] Residual excessive daytime sleepiness despite optimal CPAP therapy occurs in 5-15% of patients and may require evaluation for other sleep disorders or stimulant therapy.

Prevention Strategies

Primary Prevention:

• Weight management (maintain BMI <30)
• Regular exercise (improves upper airway muscle tone)
• Smoking cessation
• Limit alcohol consumption
• Sleep hygiene education

Secondary Prevention:

• Early recognition in high-risk populations
• Preoperative screening (STOP-BANG)
• Family screening (genetic predisposition)
• Comorbidity management (hypertension, diabetes)

Long-term Monitoring:

• Annual cardiovascular assessment
• Sleep study repeat if clinical deterioration
• CPAP pressure adjustment as needed
• Alternative therapy consideration for CPAP failures